Iterion Therapeutics, a clinical stage biotechnology company, is dedicated to developing novel cancer therapeutics for a broad range of cancers. When Iterion’s lead product, Tegavivint, demonstrated low solubility in water, they needed a partner who could not only solve their bioavailability challenges, but also develop a scalable formulation with a viable manufacturing strategy. They turned to the experts at Lubrizol Life Science Health (LLS Health). In this case study, you’ll learn how LLS Health combined its nanomilling expertise and GMP manufacturing capabilities to maximize bioavailability, improve patient experience, and take Iterion’s poorly soluble compound into clinical studies
The Role of On-Demand Manufacturing and Derisking in Accelerating Early Clinical Trial Success
June 4th 2025Small pharmaceutical companies are constantly seeking innovative solutions to streamline early clinical trials. Adaptive clinical trials offer important benefits to sponsors and patients, both from a commercial and ethical standpoint. These trials offer flexibility and efficiency, especially in the early stages, where trial protocols can be adjusted based on interim data, such as introducing new doses or modifying participant sample size. However, adjusting manufacturing demand during an adaptive trial can be complicated, and strict regulatory requirements present significant challenges. On-demand manufacturing provides a robust solution, allowing for real-time supply and demand adjustments and improved trial flexibility. This paper explores how on-demand manufacturing meets the operational needs of adaptive trials and aligns with regulatory expectations.
Fast and Efficient Sialic Acid Clone Selection Using Lectin-Based High-Throughput Screening
June 2nd 2025Glycosylation is a common and critical post-translational modification that affects protein function and therapeutic efficacy, making its monitoring and accurate quantification essential for drug development.